Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 13 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
10 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
P & X Medical from Wevelgem, company number BE0599996468, closed financial year 2025 with a result of € -109,042 after tax. For that financial year P & X Medical recorded a gross margin of € -73,960 and equity of € -177,285. Compared with financial year 2024, the result moved from € -192,577 to € -109,042. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 29, 2026.
€ -177,285
▼ € 109,042 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -109,042
▲ 43 % less loss than in 2024
Profit after tax over the fiscal year.
€ 24,394
▲ 133% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -1.8 million.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 25,355
▲ € 24,926 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 636
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -174,019 | € -121,519 | € -134,235 | € -73,960 | ▲ € 60,274 |
| Profit after taxes | € -247,621 | € -176,805 | € -192,577 | € -109,042 | ▲ € 83,535 |
| Equity | € 121,605 | € 79,800 | € -68,243 | € -177,285 | ▼ € 109,042 |
| Total debts | € 27,669 | € 29,139 | € 144,429 | € 227,991 | ▲ 58% |
| Cash | € 1,194 | € 8,182 | € 10,457 | € 24,394 | ▲ 133% |
| Retained profit | € -1,344,395 | € -1,521,200 | € -1,713,777 | € -1,822,819 | ▼ € 109,042 |
| Balance sheet total | € 149,274 | € 108,939 | € 76,186 | € 50,706 | ▼ 33% |
Key figures of P & X Medical, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to P & X Medical?
What happened at P & X Medical in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 109,042. Source: NBB ↗
- New establishment in Oostkamp. KBO
- Start of the company according to the CBE. KBO
In short
From € 247,621 loss in 2022 to € 109,042 loss in 2025.
A new publication or filing at P & X Medical? We notify you, reason included.
Follow P & X MedicalDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind P & X Medical are Nadine Vanhalst, Peter Wostyn and Emil Pot. Nadine Vanhalst is also behind VASTGOEDBEHEER ROUSERE, DE VLASBLOMME, MAGENA, SAGITTAIRE FINANCE and PARKSIDE PROMOTION. Emil Pot is also behind Allero Therapeutics.
Directors
According to the 2025 annual accounts
Nadine Vanhalst
Director
Also active at: VASTGOEDBEHEER ROUSERE, DE VLASBLOMME, MAGENA, SAGITTAIRE FINANCE, PARKSIDE PROMOTION, GNVH
Peter Wostyn
Managing director
Establishments
Establishment units
Physical locations of this company
Ballingstraat 116
8560 Wevelgem
Blauwhuisstraat 26
8020 Oostkamp
Active since 16 October 2015
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 10 companies are registered at this address.
All companies at this address →SV Center
€ 422,355 gross margin · 2025
VASTGOEDBEHEER ROUSERE same network
€ 62,743 gross margin · 2025
DE VLASBLOMME same network
€ 1.3 million gross margin · 2025
MAGENA same network
€ 501,944 gross margin · 2025
NARISART
€ 79,765 gross margin · 2025
+5 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0599.996.468
- VAT number
- BE 0599.996.468
- Registered office
- Ballingstraat 116, 8560 Wevelgem
- Names & denominations
- P & X Medical
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 6 March 2015
- Peppol
- Active · Active since 12 Nov 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Vervaardiging van meet-, controle- en navigatie-instrumenten en -apparatuur
Vervaardiging van overige farmaceutische producten
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied